These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24384805)

  • 21. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
    de Marinis F; Grossi F
    Oncologist; 2008; 13 Suppl 1():14-20. PubMed ID: 18263770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
    Krawczyk P; Kowalski DM; Wojas-Krawczyk K; Mlak R; Jaśkiewicz P; Kucharczyk T; Winiarczyk K; Krzakowski M; Milanowski J
    Chemotherapy; 2012; 58(1):60-9. PubMed ID: 22338650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
    Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J
    Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
    Li T; Ling YH; Goldman ID; Perez-Soler R
    Clin Cancer Res; 2007 Jun; 13(11):3413-22. PubMed ID: 17545550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
    Ramalingam S; Sandler AB
    Oncologist; 2006 Jun; 11(6):655-65. PubMed ID: 16794244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status.
    Chen YM; Shih JF; Fan WC; Wu CH; Chou KT; Tsai CM; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2011 May; 74(5):209-14. PubMed ID: 21550007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol 2008; 14(6):803-827.
    Bartminski W
    Rev Port Pneumol; 2009; 15(3):555-9; author reply 560-6. PubMed ID: 19526635
    [No Abstract]   [Full Text] [Related]  

  • 32. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Considerations for second-line therapy of non-small cell lung cancer.
    Stinchcombe TE; Socinski MA
    Oncologist; 2008; 13 Suppl 1():28-36. PubMed ID: 18263772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line treatment for advanced non-small cell lung cancer: how to design a clinical trial for a new agent?
    Paesmans M; Berghmans T; Sculier JP
    Lung Cancer; 2007 Feb; 55(2):135-6. PubMed ID: 17118490
    [No Abstract]   [Full Text] [Related]  

  • 35. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
    Bearz A; Garassino I; Cavina R; Favaretto A; Boccalon M; Talamini R; Berretta M; Spazzapan S; Simonelli C; Santoro A; Tirelli U
    Lung Cancer; 2008 May; 60(2):240-5. PubMed ID: 18022729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
    Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
    Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Di BS; Wei KP; Tian JH; Xiao XJ; Li Y; Zhang XH; Yu Q; Yang KH; Ge L; Huang WH; Zhang FW
    Asian Pac J Cancer Prev; 2014; 15(8):3419-24. PubMed ID: 24870732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
    Giaccone G; Gallegos Ruiz M; Le Chevalier T; Thatcher N; Smit E; Rodriguez JA; Janne P; Oulid-Aissa D; Soria JC
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6049-55. PubMed ID: 17062680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
    Goto K; Nishio M; Yamamoto N; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Fukuyama T; Tamura T
    Lung Cancer; 2013 Oct; 82(1):109-14. PubMed ID: 23910906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pemetrexed in second-line treatment of non-small-cell lung cancer.
    De Marinis F; De Petris L
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):38-42. PubMed ID: 15655935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.